ArticleBioengineered
A second-generation Bacillus cell factory for rare inositol production.
Article in Bioengineered. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Review
- Unraveling the Underlying Heavy Metal Detoxification Mechanisms ofMicroorganisms · 2021Review
- A Molecular Survey of Bacterial Species in the Guts of Black Soldier Fly Larvae (Frontiers in microbiology · 2021Article
- Efficient production of myo-inositol in Escherichia coli through metabolic engineering.Microbial cell factories · 2020Article
- A bacterial cell factory converting glucose into scyllo-inositol, a therapeutic agent for Alzheimer's disease.Communications biology · 2020Article
- Recent Advances in the Physiology of Spore Formation for Bacillus Probiotic Production.Probiotics and antimicrobial proteins · 2019Review
- Identification of Bacillus species: Implication on the quality of probiotic formulations.PloS one · 2019Article
- Review
Corrections and comments
- Comment on
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Some rare inositol stereoisomers are known to exert specific health-promoting effects, including scyllo-inositol (SI), which is a promising therapeutic agent for Alzheimer disease. We recently reported a Bacillus subtilis cell factory that performed the efficient production of SI from the cheapest and most abundant isomer myo-inositol (MI). In the cell factory all "useless" genes involved in MI and SI metabolism were deleted and overexpression of the key enzymes, IolG and IolW, was appended. It converted 10 g/L MI into the same amount of SI in 48 h of cultivation. In this addendum, we discuss further improvement in the cell factory and its possible applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.